Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Avexis Inc (AVXS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,754,292
  • Shares Outstanding, K 36,820
  • Annual Sales, $ 0 K
  • Annual Income, $ -218,050 K
  • 36-Month Beta 2.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 20.25

Price Performance

See More
Period Period Low Period High Performance
1-Month
114.97 +84.56%
on 04/06/18
213.70 -0.71%
on 04/10/18
+87.23 (+69.81%)
since 03/23/18
3-Month
102.10 +107.83%
on 02/09/18
213.70 -0.71%
on 04/10/18
+103.23 (+94.74%)
since 01/25/18
52-Week
65.54 +223.76%
on 05/31/17
213.70 -0.71%
on 04/10/18
+133.45 (+169.48%)
since 04/25/17

Most Recent Stories

More News
AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3

AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that the first...

AVXS : 211.79 (+0.57%)
AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology

- A mean increase in CHOP-INTEND of 17.3 was observed at three months post gene therapy in SMA Type 1 U.S. pivotal trial -

AVXS : 211.79 (+0.57%)
Lifshitz & Miller LLP Announces Investigation of ADT Inc., AveXis, Inc., Connecticut Water Service, Inc., Edge Therapeutics, Inc., Fairmount Santrol Holdings, Inc., Oclaro, Inc., QuinStreet, Inc. and RSP Permian, Inc.

ADT Inc. (ADT)

ADT : 9.18 (+2.11%)
CTWS : 67.95 (+0.10%)
FMSA : 5.47 (+4.79%)
RSPP : 48.22 (+1.49%)
QNST : 11.93 (+2.05%)
EDGE : 1.16 (-2.52%)
AVXS : 211.79 (+0.57%)
OCLR : 7.48 (-8.56%)
RM LAW Announces Investigation of AveXis, Inc.

RM LAW, P.C. is investigating potential claims against the board of directors of AveXis, Inc. ("AveXis" or the "Company") (NASDAQ: AVXS) concerning possible breaches of fiduciary duty and other violations...

NVS : 76.24 (-0.97%)
AVXS : 211.79 (+0.57%)
Novartis (NVS) Beats Earnings and Revenue Estimates in Q1

Novartis reported encouraging results for the first quarter as sales and earnings both topped expectations on Cosentyx and Entresto strength.

ONCE : 73.96 (-1.88%)
NVS : 76.24 (-0.97%)
GSK : 39.08 (-3.84%)
AVXS : 211.79 (+0.57%)
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of AveXis, Inc. - AVXS

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating AveXis, Inc. ("AveXis"...

NVS : 76.24 (-0.97%)
AVXS : 211.79 (+0.57%)
AveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology

AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that initial...

AVXS : 211.79 (+0.57%)
AVEXIS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout

Rigrodsky & Long, P.A.:

AVXS : 211.79 (+0.57%)
Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus

With the announcement of Novartis (NVS) acquiring AveXis, a clinical stage gene therapy company, several companies have started to develop the therapy with many of them having promising candidates in their...

QURE : 29.72 (+3.27%)
ONCE : 73.96 (-1.88%)
BMRN : 81.50 (+0.46%)
NVS : 76.24 (-0.97%)
PFE : 36.65 (-1.11%)
AVXS : 211.79 (+0.57%)
Pharma M&A Active This Week: 4 Potential Buyout Targets

Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.

AGIO : 83.98 (-0.08%)
VRTX : 154.84 (-0.53%)
BMRN : 81.50 (+0.46%)
INCY : 62.95 (+0.96%)
NVS : 76.24 (-0.97%)
AVXS : 211.79 (+0.57%)
ALXN : 106.59 (+0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company's product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant...

See More

Key Turning Points

2nd Resistance Point 213.75
1st Resistance Point 212.18
Last Price 211.79
1st Support Level 209.26
2nd Support Level 207.91

See More

52-Week High 213.70
Last Price 211.79
Fibonacci 61.8% 157.10
Fibonacci 50% 139.62
Fibonacci 38.2% 122.14
52-Week Low 65.54

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar